European cancer monoclonal Antibodies Market Size, Share and Forecast 2020-2026

European cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.0% during the forecast period. Increasing launches of monoclonal antibodies biosimilars is offering an opportunity for market growth. For instance, in April 2020, Pfizer Inc. declared the European Commission approval of RUXIENCE (rituximab). It is a monoclonal antibody and biosimilar to MabThera (rituximab), which aims to treat granulomatosis with polyangiitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, rheumatoid arthritis, microscopic polyangiitis, and pemphigus vulgaris. The biosimilars' approval including RUXIENCE is an essential development to treat certain cancers and autoimmune conditions. It offers effectiveness to improve access to treatment access while minimizing healthcare costs. 

To Request a Sample of our Report on European cancer monoclonal Antibodies Market:  https://www.omrglobal.com/request-sample/european-cancer-monoclonal-antibodies-market

Additionally, in February 2018, Celltrion Healthcare declared the European Commission approval of Herzuma (trastuzumab biosimilar, CT-P6). This is intended for all indications offered by reference trastuzumab in the EU. It is the third Celltrion Healthcare product that was approved in the EU and established on the company’s increasing biosimilar portfolio. This has led the company to market Herzuma in all 28 EU member states and the European Economic Area to treat patients suffering from metastatic breast cancer, early breast cancer, or metastatic gastric cancer. These launches of biosimilars represent the European Commission's focus towards increasing access to cancer treatment in the region, which in turn, will accelerate the market growth.

 Scope of the European Cancer Monoclonal Antibodies Market

Market Coverage

·        Market number available for 2019-2026

·        Base year- 2019

·        Forecast period- 2020-2026

·        Segment Covered- By Type and Application

·        Countries Covered- UK, Germany, France, Spain, Italy, and Rest of Europe

·        Competitive Landscape- AstraZeneca plc, Pfizer Inc., F- Hoffman La-Roche AG, Novartis AG, and Mylan N.V.

Recent Strategic Initiatives in the European Cancer Monoclonal Antibodies Market

·        In June 2020, Sanofi S.A. declared the European Commission approval of Sarclisa (isatuximab) along with dexamethasone (pom-dex) and pomalidomide to treat adults suffering from relapsed and refractory multiple myeloma. It is a monoclonal antibody that attaches to a particular epitope on the CD38 receptor of MM cells.

·        In January 2020, Roche declared that the European Commission has permitted conditional marketing authorization for Polivy (polatuzumab vedotin), along with bendamustine plus MabThera (rituximab) (BR), to treat adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant.

(Get 15% Discount on Buying this Report)

A full Report of European cancer monoclonal Antibodies Market is Available at:  https://www.omrglobal.com/industry-reports/european-cancer-monoclonal-antibodies-market

Key questions addressed by the report

·        What is the market growth rate?

·        Which country/segment dominates the market in the base year?

·        Which country/segment will project the fastest growth in the market?

·        How COVID-19 impacted the market?

Ø  Recovery Timeline

Ø  Deviation from the pre-COVID forecast

Ø  Most affected country/segment

·        Who is the leader in the market?

·        How players are addressing challenges to sustain growth?

·        Where is the investment opportunity?

European Cancer Monoclonal Antibodies Market-Segmentation

By Type

·        Naked 

·        Conjugated

·        Others (Bispecific)

By Application

·        Breast Cancer

·        Liver Cancer

·        Blood Cancer

·        Brain Cancer

·        Colorectal Cancer

·        Others

European Cancer Monoclonal Antibodies Market– Segment by Country

·        UK

·        Germany

·        Spain

·        France

·        Italy

Rest of Europe

Company Profiles

·        AstraZeneca plc

·        Bayer AG

·        Bristol-Myers Squibb Co.

·        F. Hoffmann-La Roche AG

·        Genmab A/S

·        GlaxoSmithKline plc

·        Innate Pharma S.A.

·        Mylan N.V.

·        Novartis AG

·        Pfizer Inc.

Reasons to Buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @  https://www.omrglobal.com/report-customization/european-cancer-monoclonal-antibodies-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404


Comments

Post a Comment

Popular posts from this blog

European Data Backup and Recovery Market Size, Share, Analysis, Industry Report and Forecast 2019-2025

  European Data Backup and Recovery Market are expected to reach $5.7 billion in 2027, growing at a CAGR of 9.5% during the forecast period (2021-2027). Factors responsible for the growth of the market in Europe are well-developed telecommunication infrastructure, high internet penetration, high adoption of cloud-based devices among people and organization. Regulations regarding the data localization such as GDPR by the European Union and countries own data localization and protection act are providing growth to the market. Major economies which are expected to hold a considerable market are UK, Germany, France, Italy, and Spain. These economies are part of the European Union, which covers most of the continent. The aim of the European Union was to increase economic cooperation and encourage free trade among countries. To Request a Sample of our Report on European Data Backup and Recovery Market :   https://www.omrglobal.com/request-sample/european-data-backup-recovery-...
Read more

Insect Repellent Market Is Likely to Experience a Tremendous Growth by 2031

This informative Insect Repellent Market report provides new method and covers foremost regions such as Latin America, Middle East, North America, Europe, Africa and Asia Pacific. Making most out of the consumer insights and market opportunities, market players can boost up the revenue rate of their business. It also permits key organizations to make communication with customers and know their demands for making right investment in the product development. By increasing the product portfolio by referring the important market data provided in this Insect Repellent Market research report, key players can grow and expand their business forward. Continuously developing customer demands are also described in this global report to help new entrants make required changes in the final product launch and then bring into the market. It becomes easy for key players to prioritize the demands and requirements of target audience and have complete understanding of end-user experience with the help o...
Read more

Asia-Pacific Urban Air Mobility Market Growth, Size, Share, Industry Report and Forecast 2019-2025

The Asia-Pacific urban air mobility market is estimated to grow at a CAGR of 12.6% during the forecast period. The Asia-Pacific urban air mobility market is segmented on the basis of component and operation. Based on the component, the market is further segmented into infrastructure and platform. The infrastructure segment is further segmented into charging stations, traffic management, and others whereas, the platform segment is further classified into air taxi, personal air vehicle, air ambulance, and others. The platform segment dominated the global urban air mobility market. To Request a Sample of our Report on Asia-Pacific Urban Air Mobility Market :   https://www.omrglobal.com/request-sample/asia-pacific-urban-air-mobility-market Asia-Pacific is home to several emerging economies and is seen as the potential market for the UAM owing to growing urbanization coupled with increasing traffic congestion and increasing high-income groups in the region. The growth of the As...
Read more